Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||
current assets: | |||||||||||||||||||
cash and cash equivalents | 618,067,000 | 470,266,000 | 446,184,000 | 432,859,000 | 340,300,000 | 339,007,000 | 238,903,000 | 202,904,000 | 391,643,000 | 395,258,000 | 384,261,000 | ||||||||
accounts receivable | 219,837,000 | 282,931,000 | 214,059,000 | 153,904,000 | 138,852,000 | 183,214,000 | 165,071,000 | 119,749,000 | 105,523,000 | 88,925,000 | 125,276,000 | 92,890,000 | 88,220,000 | 98,027,000 | 84,527,000 | 58,512,000 | 47,671,000 | 66,472,000 | 49,458,000 |
investments - current | 26,013,000 | 33,511,000 | 33,360,000 | 37,791,000 | 40,676,000 | 24,701,000 | 62,809,000 | 115,914,000 | |||||||||||
prepaid expenses and other current assets | 121,407,000 | 93,414,000 | 80,883,000 | 37,084,000 | 53,779,000 | 52,191,000 | 53,856,000 | 44,970,000 | 45,878,000 | 77,185,000 | 57,894,000 | 42,107,000 | 36,493,000 | 34,337,000 | 32,829,000 | 27,747,000 | 29,236,000 | 31,801,000 | 26,773,000 |
total current assets | 985,324,000 | 880,122,000 | 774,486,000 | 661,638,000 | 573,607,000 | 599,113,000 | 520,639,000 | 483,537,000 | 666,970,000 | 683,617,000 | 670,914,000 | 544,546,000 | 692,159,000 | 585,598,000 | 566,191,000 | 552,859,000 | 577,392,000 | 592,891,000 | 604,648,000 |
property and equipment | 67,017,000 | 69,523,000 | 68,504,000 | 67,139,000 | 64,692,000 | 62,430,000 | 57,211,000 | 51,901,000 | 47,162,000 | 43,032,000 | 39,613,000 | 37,169,000 | 35,577,000 | 33,405,000 | 31,747,000 | 30,358,000 | 31,505,000 | 29,532,000 | 28,403,000 |
right of use asset | 7,338,000 | 7,579,000 | 7,750,000 | 7,818,000 | 8,124,000 | 8,085,000 | 8,549,000 | 9,959,000 | 10,472,000 | 10,613,000 | 5,077,000 | 5,825,000 | 6,085,000 | 6,565,000 | 7,354,000 | 8,272,000 | 8,876,000 | 9,577,000 | |
goodwill | 32,060,000 | 32,060,000 | 34,192,000 | 34,826,000 | 34,826,000 | 34,826,000 | 34,826,000 | 34,826,000 | |||||||||||
intangible assets | 4,550,000 | 4,550,000 | 4,550,000 | 4,550,000 | 4,550,000 | 5,201,000 | 5,224,000 | 5,252,000 | |||||||||||
other assets | 6,325,000 | 6,316,000 | 6,135,000 | 6,092,000 | 6,488,000 | 6,603,000 | 6,781,000 | 6,405,000 | 6,082,000 | 6,151,000 | 5,956,000 | 6,035,000 | 6,104,000 | 4,960,000 | 4,977,000 | 4,709,000 | 4,545,000 | 3,447,000 | |
total assets | 1,102,614,000 | 1,000,150,000 | 895,617,000 | 782,063,000 | 692,287,000 | 716,258,000 | 633,230,000 | 591,880,000 | 770,792,000 | 783,546,000 | 761,751,000 | 633,863,000 | 777,543,000 | 666,777,000 | 646,614,000 | 630,895,000 | 656,927,000 | 670,056,000 | 679,344,000 |
liabilities and stockholders' equity | |||||||||||||||||||
current liabilities: | |||||||||||||||||||
medical expenses payable | 528,796,000 | 455,154,000 | 396,734,000 | 289,788,000 | 297,125,000 | 315,369,000 | 276,464,000 | 205,399,000 | 203,435,000 | 207,198,000 | 185,670,000 | 170,135,000 | 171,395,000 | 173,871,000 | 154,963,000 | 125,886,000 | 128,775,000 | 136,478,000 | 128,673,000 |
accounts payable and accrued expenses | 34,009,000 | 31,357,000 | 28,032,000 | 22,126,000 | 25,394,000 | 23,336,000 | 22,671,000 | 23,511,000 | 25,356,000 | 21,271,000 | 22,865,000 | 32,288,000 | 20,691,000 | 14,975,000 | 16,443,000 | 17,431,000 | 16,557,000 | 14,615,000 | 19,639,000 |
accrued compensation | 48,280,000 | 43,016,000 | 32,353,000 | 39,931,000 | 33,951,000 | 32,834,000 | 31,607,000 | 34,112,000 | 35,141,000 | 25,905,000 | 24,571,000 | 27,538,000 | 31,411,000 | 24,868,000 | 23,564,000 | 23,928,000 | 29,810,000 | 22,643,000 | 21,481,000 |
total current liabilities | 611,085,000 | 529,527,000 | 457,119,000 | 351,845,000 | 358,083,000 | 371,539,000 | 330,742,000 | 263,022,000 | 410,274,000 | 401,851,000 | 374,187,000 | 229,961,000 | 340,264,000 | 213,714,000 | 194,970,000 | 167,245,000 | 175,142,000 | 173,736,000 | 169,793,000 |
long-term debt, net of debt issuance costs | 322,736,000 | 322,295,000 | 321,855,000 | 321,428,000 | 211,742,000 | 162,030,000 | 161,813,000 | 161,595,000 | 161,378,000 | 161,121,000 | 160,902,000 | 160,677,000 | 153,931,000 | 152,256,000 | 150,620,000 | 148,967,000 | 147,333,000 | 145,734,000 | |
long-term portion of lease liabilities | 6,922,000 | 7,361,000 | 7,648,000 | 7,835,000 | 8,191,000 | 8,179,000 | 8,441,000 | 8,974,000 | 9,318,000 | 9,205,000 | 2,503,000 | 3,698,000 | 4,458,000 | 5,428,000 | 6,103,000 | 6,975,000 | 7,743,000 | 8,607,000 | 9,565,000 |
total liabilities | 940,743,000 | 859,183,000 | 786,622,000 | 681,108,000 | 576,660,000 | 591,460,000 | 501,213,000 | 433,809,000 | 581,187,000 | 572,434,000 | 537,811,000 | 394,561,000 | 505,399,000 | 373,073,000 | 353,329,000 | 324,840,000 | 331,852,000 | 329,676,000 | 325,092,000 |
commitments and contingencies | |||||||||||||||||||
stockholders' equity: | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 shares authorized as of september 30, 2025 and december 31, 2024, respectively; no shares issued and outstanding as of september 30, 2025 and december 31, 2024 | |||||||||||||||||||
common stock | 200,000 | 198,000 | 198,000 | 192,000 | 191,000 | 191,000 | 191,000 | 189,000 | 189,000 | 188,000 | 188,000 | 187,000 | 187,000 | 187,000 | 187,000 | 188,000 | 188,000 | 188,000 | 188,000 |
additional paid-in capital | 1,159,682,000 | 1,142,509,000 | 1,125,340,000 | 1,107,952,000 | 1,091,561,000 | 1,074,303,000 | 1,057,519,000 | 1,037,015,000 | 1,021,363,000 | 1,007,794,000 | 992,158,000 | 970,180,000 | 947,295,000 | 928,608,000 | 916,594,000 | 880,708,000 | 851,895,000 | 821,384,000 | 790,509,000 |
accumulated deficit | -998,011,000 | -1,001,740,000 | -1,017,407,000 | -1,008,293,000 | -977,202,000 | -950,789,000 | -926,779,000 | -880,258,000 | -833,049,000 | -798,002,000 | -769,525,000 | -732,241,000 | -675,338,000 | -635,091,000 | -623,511,000 | -574,856,000 | -527,023,000 | -481,207,000 | -436,445,000 |
total alignment healthcare, inc. stockholders' equity | 161,871,000 | 140,967,000 | 108,131,000 | 99,851,000 | 114,550,000 | 123,705,000 | 130,931,000 | 156,946,000 | 188,503,000 | 209,980,000 | 222,821,000 | 238,126,000 | 272,144,000 | 293,704,000 | 293,270,000 | 306,040,000 | 325,060,000 | 340,365,000 | |
noncontrolling interest | 864,000 | 1,104,000 | 1,077,000 | 1,093,000 | 1,086,000 | 1,125,000 | 1,102,000 | 1,132,000 | 1,119,000 | 1,176,000 | 15,000 | 15,000 | 15,000 | 15,000 | |||||
total stockholders' equity | 161,871,000 | 140,967,000 | 108,995,000 | 100,955,000 | 115,627,000 | 124,798,000 | 132,017,000 | 158,071,000 | 189,605,000 | 211,112,000 | 223,940,000 | 239,302,000 | 272,144,000 | 293,704,000 | 293,285,000 | 306,055,000 | 325,075,000 | 340,380,000 | 354,252,000 |
total liabilities and stockholders' equity | 1,102,614,000 | 1,000,150,000 | 895,617,000 | 782,063,000 | 692,287,000 | 716,258,000 | 633,230,000 | 591,880,000 | 770,792,000 | 783,546,000 | 761,751,000 | 633,863,000 | 777,543,000 | 666,777,000 | 646,614,000 | 630,895,000 | 656,927,000 | 670,056,000 | 679,344,000 |
preferred stock, .001 par value; 100,000,000 shares authorized as of june 30, 2025 and december 31, 2024, respectively; no shares issued and outstanding as of june 30, 2025 and december 31, 2024 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 shares authorized as of march 31, 2025 and december 31, 2024, respectively; no shares issued and outstanding as of march 31, 2025 and december 31, 2024 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 shares authorized as of december 31, 2024 and 2023, respectively; no shares issued and outstanding as of december 31, 2024 and 2023 | |||||||||||||||||||
current maturities of long-term debt | 1,613,000 | ||||||||||||||||||
long-term debt, net of current maturities and debt issuance costs | 210,386,000 | ||||||||||||||||||
preferred stock, .001 par value; 100,000,000 shares authorized as of september 30, 2024 and december 31, 2023, respectively; no shares issued and outstanding as of september 30, 2024 and december 31, 2023 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 shares authorized as of june 30, 2024 and december 31, 2023, respectively; no shares issued and outstanding as of june 30, 2024 and december 31, 2023 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 shares authorized as of march 31, 2024 and december 31, 2023, respectively; no shares issued and outstanding as of march 31, 2024 and december 31, 2023 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 shares authorized as of december 31, 2023 and 2022, respectively; no shares issued and outstanding as of december 31, 2023 and 2022 | |||||||||||||||||||
short-term investments | 123,926,000 | 122,249,000 | 103,483,000 | ||||||||||||||||
goodwill and intangible assets | 40,106,000 | 40,133,000 | 40,191,000 | 40,288,000 | 37,618,000 | 36,249,000 | 36,345,000 | 35,116,000 | 35,213,000 | 35,310,000 | 34,563,000 | ||||||||
deferred premium revenue | 146,342,000 | 147,477,000 | 141,081,000 | 116,767,000 | |||||||||||||||
preferred stock, .001 par value; 100,000,000 and 100,000,000 shares authorized as of september 30, 2023 and december 31, 2022, respectively; no shares issued and outstanding as of september 30, 2023 and december 31, 2022 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 and 100,000,000 shares authorized as of june 30, 2023 and december 31, 2022, respectively; no shares issued and outstanding as of june 30, 2023 and december 31, 2022 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 and 100,000,000 shares authorized as of march 31, 2023 and december 31, 2022, respectively; no shares issued and outstanding as of march 31, 2023 and december 31, 2022 | |||||||||||||||||||
cash | 409,549,000 | 567,446,000 | 453,234,000 | 448,835,000 | 466,600,000 | 500,485,000 | 494,618,000 | 528,417,000 | |||||||||||
preferred stock, .001 par value; 100,000,000 and 100,000,000 shares authorized as of december 31, 2022 and december 31, 2021, respectively; no shares issued and outstanding as of december 31, 2022 and december 31, 2021 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 and 0 shares authorized as of september 30, 2022 and december 31, 2021, respectively; no shares issued and outstanding as of september 30, 2022 and december 31, 2021 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 and 0 shares authorized as of june 30, 2022 and december 31, 2021, respectively; no shares issued and outstanding as of june 30, 2022 and december 31, 2021 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 and 0 shares authorized as of march 31, 2022 and december 31, 2021, respectively; no shares issued and outstanding as of march 31, 2022 and december 31, 2021 | |||||||||||||||||||
right of use assets | 7,853,000 | ||||||||||||||||||
preferred stock, .001 par value; 100,000,000 and 0 shares authorized as of december 31, 2021 and december 31, 2020, respectively; no shares issued and outstanding as of december 31, 2021 and december 31, 2020 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 and 0 shares authorized as of september 30, 2021 and december 31, 2020, respectively; no shares issued and outstanding as of september 30, 2021 and december 31, 2020 | |||||||||||||||||||
preferred stock, .001 par value; 100,000,000 and 0 shares authorized as of june 30, 2021 and december 31, 2020 respectively; no shares issued and outstanding as of june 30, 2021 and december 31, 2020 | |||||||||||||||||||
restricted and other assets | 2,153,000 | ||||||||||||||||||
preferred stock, .001 par value; 100,000,000 and 0 shares authorized as of march 31, 2021 and december 31, 2020 respectively; no shares issued and outstanding as of march 31, 2021 and december 31, 2020 |
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.